Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | AMY1A | P0DUB6 | 4/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.54 |
| ▸ | METAP1 | P53582 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26426632 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3AALDH1A1KDM4E | |
| SCHEMBL10851751 | 0.89 | PDE5A (0.80) | PDE5APDE3BPDE3AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL7278014 | 0.87 | PDE5A (0.80) | PDE5APDE3BPDE3AALDH1A1KDM4E | |
| SCHEMBL2096956 | 0.83 | AMY1A (0.76) | PDE5AALDH1A1KDM4EHPGDAURKA | |
| SCHEMBL31027930 | 0.83 | AMY1A (0.76) | PDE5AALDH1A1KDM4EHPGDAURKA | |
| SCHEMBL10734339 | 0.82 | PDE5A (0.70) | PDE5APDE3BPDE3AALDH1A1KDM4E | |
| SCHEMBL29870938 | 0.82 | PDE5A (0.70) | PDE5APDE3BPDE3AALDH1A1KDM4E | |
| SCHEMBL26426638 | 0.82 | PDE5A (0.70) | PDE5APDE3BPDE3AALDH1A1KDM4E | |
| SCHEMBL26426630 | 0.81 | PDE5A (0.67) | PDE5APDE3BPDE3AALDH1A1KDM4E | |
| SCHEMBL10518202 | 0.79 | PDE5A (0.65) | PDE5APDE3BPDE3AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| EP-4110777-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | SARS1, TPI1, TPMT | PDE5A 1378/4885PDE3B 2284/4885PDE3A 1603/4885 |
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | SARS1, TPMT, ZC3HAV1 | PDE5A 2466/4885PDE3B 3854/4885PDE3A 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.